BRS201

BRS201 is hydroxocobalamin - the same molecule sold as Cyanokit, an FDA-approved cyanide antidote - being repurposed for mild ulcerative colitis (UC) in a Phase 2 randomized double-blind crossover trial at Brigham and Women's Hospital, with a primary endpoint measuring reduction of hydrogen sulfide (H2S) metabolites in plasma at 4 weeks [1]. The intervention identity matters: hydroxocobalamin is a vitamin B12 analog with documented capacity to bind H2S and cyanide through its central cobalt atom, so this is not a novel chemical entity but a repositioning bet that an approved cyanide scavenger can also scrub colonic sulfide. There is no disclosed corporate developer, no FDA designation for the UC indication, and the parallel BWH DOLPHIN trial (NCT05835505) tests the same compound in primary sclerosing cholangitis with an alkaline phosphatase endpoint [3] - so the cross-program link is the molecule, not the H2S mechanism per se. Estimated primary completion: December 1, 2026 [1]. Treat as an academic repurposing study, not a commercial-stage asset.

Phase 2, recruiting, n=20, single-academic-sponsor (Brigham and Women's Hospital), randomized double-blind placebo-controlled crossover with estimated primary completion December 1, 2026 [1]. The compound IS disclosed in the ClinicalTrials.gov intervention record as BRS201 = hydroxocobalamin, dosed at 1.2-2.4 g orally daily plus co-administered oral butyrate 240 mg daily, with one arm adding 2.5 g IV [1] - our database previously carried it as 'investigational' because the trial title obscured the active. The 'BRS' prefix does not correspond to any disclosed corporate developer in public databases; it appears to be an investigator-assigned designator, not a company code. No FDA breakthrough, fast-track, orphan, or accelerated approval designations apply to this UC indication (hydroxocobalamin is approved as Cyanokit for cyanide poisoning, a separate indication). No NDA/BLA timeline. The companion DOLPHIN trial NCT05835505 uses the same compound in primary sclerosing cholangitis with an alkaline phosphatase endpoint (primary completion June 1, 2026) [3], and NCT06420492 is a separate BWH acute colitis program [2] - taken together this looks like an investigator-led hydroxocobalamin repositioning portfolio rather than a sponsored drug development plan. Realistic expectation: a biomarker readout, possibly a paper, no regulatory filing on the horizon. Treat any commercial timeline number you see attached to this node as fabricated.

With BRS201 disclosed as hydroxocobalamin, the mechanism is far less opaque than the trial title suggests. Hydroxocobalamin (a vitamin B12 form, marketed as Cyanokit) is a cobalt-centered cofactor that binds and inactivates several reactive sulfur and cyanide species - including hydrogen sulfide - by coordinating them to its central metal atom. The working model for BRS201 in UC is therefore: oral hydroxocobalamin reaches the colon, scavenges H2S produced by sulfate-reducing bacteria, and reduces local sulfide toxicity to colonocytes. Hydrogen sulfide is a gas produced in the colon by sulfate-reducing bacteria fermenting dietary sulfur. At low concentrations H2S is a normal signaling molecule, but at the levels reached in some UC patients it poisons colonocyte metabolism - it blocks cytochrome c oxidase, the same mitochondrial enzyme cyanide blocks - and damages the mucus layer that keeps gut bacteria from reaching the epithelium [4]. The hypothesis that excess colonic H2S drives UC has been around for decades, supported by elevated sulfide in UC stool, depletion of butyrate (the primary energy source for colonocytes), and the fact that bismuth (e.g., bismuth subsalicylate, Pepto-Bismol), which also chemically binds sulfide, has historically helped some UC patients [4][5]. The co-administered butyrate in the BRS201 regimen reinforces this model: scavenge the toxin with hydroxocobalamin, restore colonocyte fuel with butyrate. The biology is plausible and not new; what's novel is using an approved cyanide antidote orally as a directed H2S scavenger in UC.

NCT06420375, Phase 2, randomized double-blind placebo-controlled crossover (correcting an earlier read of 'open-label'), n=20, 4-week treatment periods in counterbalanced order, sponsored by Brigham and Women's Hospital, estimated primary completion December 1, 2026 [1]. Each participant receives active BRS201 (hydroxocobalamin) and matching placebo, both arms with co-administered oral butyrate. Population: active mild UC - not moderate-to-severe, which is the population every commercial UC program targets, including biologics like vedolizumab (a gut-selective anti-α4β7 integrin antibody approved for moderate-to-severe UC, ~$5B+ in annual sales) and ustekinumab (an anti-IL-12/23 antibody also approved for moderate-to-severe UC), JAK inhibitors such as tofacitinib, and S1P receptor modulators like ozanimod (a newer oral class that prevents lymphocytes from leaving lymph nodes, reducing gut inflammation). The primary endpoint is a plasma biomarker (H2S metabolites), not a clinical endpoint such as Mayo score reduction (Mayo: a 0-12 composite of stool frequency, rectal bleeding, endoscopic findings, and physician global assessment), endoscopic remission (visible inflammation resolution on colonoscopy), or mucosal healing (regrowth of the gut lining, the gold-standard endpoint for modern UC trials). That choice tells you the trial is powered to detect mechanism, not patient benefit. Status: recruiting. Enrollment of 20 in mild UC at a single academic center is achievable but slow; primary completion is committed at December 1, 2026, though crossover designs at n=20 often slip [1]. This is a well-designed proof-of-mechanism study and a poorly-designed efficacy study - fine if read as the former. Anyone treating a positive H2S-metabolite delta in 20 crossover patients as a green light for mild UC efficacy is overreading.

Our model estimates a 3% chance this drug is eventually approved. That starting point comes from the historical approval rate for Phase 2 drugs in this area, which is about 23%. The estimate is then pulled down by several factors: heavier-than-usual blinding, the sponsor's thin or weak approval record, weak or limited earlier-phase results, and smaller-than-typical enrollment for this phase. The remaining factors are close to average and leave the number roughly unchanged.

Efficacy risk: the trial reads out a biomarker, not a clinical endpoint, so a 'positive' result still leaves the central question - does reducing colonic H2S actually heal mild UC mucosa - unanswered. The H2S hypothesis has been around since the 1990s and no drug working through directed H2S modulation has ever reached UC approval (bismuth's incidental sulfide-binding doesn't count as a targeted therapy), which is itself a soft negative signal [4][5]. Mild UC is also the wrong commercial target. Mild UC represents roughly 30-40% of the ~900,000 US UC patients, and 5-ASAs (mesalamine generics, ~$100-400 per month) already work well in most of them. Any new mild-UC drug needs to beat near-free generics on tolerability or convenience, not just placebo - and the moderate-to-severe segment that drives the ~$10B+ global UC market is locked up by biologics (vedolizumab and ustekinumab at ~$20,000-60,000 per year of treatment) and oral small molecules. Safety risk: comparatively low for this stage, because hydroxocobalamin's profile is well-characterized from decades of Cyanokit and B12 use; unknowns are chronic high oral dosing exposure and any colonic-specific tolerability. Execution risk is the biggest one: academic sponsor, no disclosed corporate partner, n=20 crossover, single site, primary completion 2026-12-01 with no external readout date beyond that [1]. Commercial risk: even with a clean Phase 2, this needs a developer to pick it up, fund a 300+ patient registrational trial in moderate UC, and price against generic 5-ASAs and entrenched biologics. Most assets at this stage don't make it - though a repositioning angle on an already-approved compound is one of the cheaper paths through that gauntlet, if a sponsor materializes.

Noise for now, with two specific reasons to check back. This is an academic proof-of-mechanism crossover trial in the wrong UC severity bucket for commercial relevance, sponsored by a hospital rather than a developer, reading out a biomarker rather than clinical efficacy - but the active is hydroxocobalamin, already FDA-approved for cyanide poisoning, which materially changes the regulatory math if anyone wants to pursue a UC indication. The 30% PoS our model assigns is anchored on a Phase 2 progression base rate (not an approval rate) and should not be read as a commercial-grade probability; there is no commercial UC program here yet. Mild UC represents ~30-40% of the ~900,000 US UC patients against a global UC market of ~$10B+ dominated by moderate-to-severe biologics, so the addressable commercial slice from this trial as-designed is small even if the biology works. The two signals that would change the picture: (1) disclosure of a corporate developer or a patent filing on hydroxocobalamin-for-UC or H2S modulation (we found no public patent activity by BWH on this combination in standard searches - absence of evidence, not evidence of absence), or (2) a Phase 2 readout showing H2S reduction that tracks with Mayo score improvement, even in a small crossover. Either would justify upgrading from research curiosity to watchlist. Until then, BRS201 belongs in the same bucket as every other BWH translational repositioning program - interesting biology, real investigator, no commercial pathway visible. Check back at the December 1, 2026 estimated primary completion or when ClinicalTrials.gov shows a results posting, whichever comes first [1]. Don't read commercial-pipeline coverage of this node - there isn't one to cover.